In 2004 was created China-Belgium Direct Equity Investment Fund, which is appeared as VC.
Deals in the range of 10 - 50 millions dollars are the general things for fund. The fund is generally included in less than 2 deals every year. The important activity for fund was in 2019.
Among the most popular portfolio startups of the fund, we may highlight Immunochina. We can highlight the next thriving fund investment areas, such as Pharmaceutical, Medical Device. Besides, a startup needs to be aged 4-5 years to get the investment from the fund.
The standard case for the fund is to invest in rounds with 3 partakers. Despite the China-Belgium Direct Equity Investment Fund, startups are often financed by Thiel Capital, ShengJing360, Legend Capital. The meaningful sponsors for the fund in investment in the same round are Shougang Fund, Sherpa Venture Capital, Qingzhe Capital.
We also calculated 1 valuable employee in our database.
Related Funds
| Fund Name | Location |
| Cathay Financial Holding | Taipei, Taiwan |
| Changxin Xinxi | China, Jiangxi, Jiujiang |
| Duchossois Capital Management | Chicago, Illinois, United States |
| EBSCO | Ipswich, Suffolk, United Kingdom |
| European regional development fund (ERDF) | Belgium, Brussels, Brussels Hoofdstedelijk Gewest |
| Honeywell International | Morristown, New Jersey, United States |
| Insigma Technology | New York, New York, United States |
| JL Company I LLC | - |
| LongeVC | Lugano, Switzerland, Ticino |
| MAW Investments | - |
| Municipal Employee Retirement System | Lansing, Michigan, United States |
| Phelps Dodge International Corporation | New York, New York, United States |
| Score Capital | China, Shanghai |
| Security Capital | - |
| SK Ventures | California, San Francisco, United States |
| SKU | Austin, Texas, United States |
| Starboard Capital Partners | Connecticut, Southport, United States |
| Tradeshift | California, San Francisco, United States |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Qinghai Lihao | $340M | 27 Sep 2022 | Guizhou, Liaoning, China | ||
Wego | $155M | 29 Oct 2021 | Nanshan, Hunan, China | ||
Immunochina | $21M | 22 Jan 2019 | Dongcheng District, Beijing, China | ||
Ruiquan Caring | $2M | 29 Oct 2018 | Gulou District, Fujian |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Qinghai Lihao | $340M | 27 Sep 2022 | Guizhou, Liaoning, China | ||
Wego | $155M | 29 Oct 2021 | Nanshan, Hunan, China | ||
Immunochina | $21M | 22 Jan 2019 | Dongcheng District, Beijing, China | ||
Ruiquan Caring | $2M | 29 Oct 2018 | Gulou District, Fujian |
